The ascendancy of Viagra and its impact on the medicinal landscape presents a complex question for investors. While the first sales statistics were remarkable, the exclusivity has lapsed, leading to a flood of generic alternatives that are eroding revenue. Furthermore, the market is facing issues related to aging trends and changing healthcare poli